Figure 2.

Phase 1: High-throughput screening of the proprietary compound library with the isogenic mouse embryonic fibroblast (MEF) panel. The isogenic MEF panel was used to conduct high-throughput screening with Sanofi’s compound library (923,000 compounds in the primary screen and 8376 compounds in the backscreen). In Phase 1, 696 active compounds were identified. 19 clusters and 8 singletons were discarded based on the biological profile and drug likeness. 126 compounds (28 clusters, 10 singletons, and 1 natural product) were ultimately selected for secondary assays for Phase 2.